The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| QLGN | -32.65% | -99.84% | -72.21% | -100% |
| S&P | +16.9% | +95.99% | +14.39% | +124% |
Qualigen Therapeutics, Inc. is a biotechnology company focused on developing therapeutics for the treatment of cancer and infectious diseases. The company's cancer therapeutics pipeline includes ALAN (AS1411-GNP), RAS-F3 and STARS. ALAN (AS1411-GNP) is a DNA coated gold nanoparticle cancer drug candidate that has the potential to target various types of cancer with minimal side effects. RAS-F3 is a small molecule RAS oncogene protein-protein inhibitor for blocking RAS mutations that lead to tumor formation, especially in pancreatic, colorectal and lung cancers. STARS is a DNA/RNA-based treatment device for removal from circulating blood of precisely targeted tumor-produced and viral compounds. The company was founded on March 29, 2004 and is headquartered in Carlsbad, CA.
| Q2 2025 | YOY Change | |
|---|---|---|
| Revenue | $0.00M | 0.0% |
| Gross Profit | $0.00M | 0.0% |
| Market Cap | $2.51M | 124.4% |
| Market Cap / Employee | $0.63M | 0.0% |
| Employees | 4 | 0.0% |
| Net Income | -$1.69M | -14.1% |
| EBITDA | -$1.68M | 3.3% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q2 2025 | YOY Change | |
|---|---|---|
| Net Cash | $0.33M | 179.4% |
| Accounts Receivable | $3.31M | 0.0% |
| Inventory | 0 | 0.0% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $0.00M | 0.0% |
| Short Term Debt | $3.62M | 116.6% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -310.49% | -176.4% |
| Return On Invested Capital | 22.26% | -84.1% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$1.10M | 25.5% |
| Operating Free Cash Flow | -$1.10M | 25.5% |
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | -2.18 | -1.08 | -0.93 | -0.83 | 160.22% |
| Price to Sales | 0.90 | 1.46 | - | ||
| Price to Tangible Book Value | -19.16 | -1.08 | -0.93 | -0.83 | -94.80% |
| Enterprise Value to EBITDA | -3.43 | -5.73 | -3.28 | -7.02 | 327.16% |
| Return on Equity | -505.6% | -1656.2% | -2140.5% | - | |
| Total Debt | $1.43M | $0.00M | $0.84M | $3.62M | 116.57% |
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
